Tris Pharma created the LiquiXR® drug delivery technology, which has led to the development of multiple first-in-category products. This proprietary technology is the foundation of our branded portfolio, and has enabled numerous successful development partnerships.
Tris Pharma is actively seeking partnership opportunities to further leverage the unique capabilities of our platform. Please contact us to learn more.
- Ion exchange polymer chemistry enables continuous release of the medication throughout the day
- Suspension formulations allow for dose titration in smaller increments
Features of LiquiXR® technology include:
Enables sustained (up to 24 hours) release in traditionally immediate-release (IR) forms, driving differentiated convenience and compliance.
Liquid products enable fine-tuningof dose titration vs discrete dosing inherent in solid dosage forms.
Multiple dosage forms
Same micro-sized particles can be adapted into a wide variety of different dosage forms with same PK profile.
Ideal for patients who have difficulty swallowing pills, including pediatric, geriatric and dysphagic adult populations.
Fine, coated particles provide taste-masking effect and a pleasant mouthfeel.
Two or more drugs can be combined into a single product, with each meeting its desired PK profile.
Tris Pharma’s technology is protected by multilayered patent estate and trade secrets, providing significant barrier to competition.
Easily taken on the go
Chewable tablets are convenient while traveling and can be packaged as an appropriate unit dose.
Robust and specialized coating process creates consistent release profiles.
Together, we can achieve more.